Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid : an ambispective multicentre case series
Planella-Fontanillas, Nidia (Institut Hospital del Mar d'Investigacions Mèdiques)
Bosch-Amate, Xavier (Hospital Clínic i Provincial de Barcelona)
Jiménez Antón, Alicia (Hospital Universitario Puerta del Mar (Cadis, Andalusia))
Moreno Vílchez, Carlos (Hospital Universitari de Bellvitge)
Gamo Guerrero, María (Hospital Universitario Infanta Leonor)
Blanes Martínez, María del Mar (Hospital General Universitario de Alicante (Alacant, País Valencià))
Ballester-Martínez, Asunción (Hospital Universitario Ramón y Cajal (Madrid))
Bassas Freixas, Patrícia (Hospital Universitari Vall d'Hebron)
Castaño Fernández, Juan Luis (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Estébanez Corrales, Andrea (Hospital Universitari Doctor Peset (València))
Suarez Fernández, Ricardo (Hospital General Universitario Gregorio Marañón)
Santos-Alarcón, Sergio (Hospital Virgen de los Lirios)
Bauzá Alonso, Ana (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Torrent, Marina (Hospital Santa María del Rosell de Cartagena)
Ballano Ruiz, A. (Hospital Universitario del Henares ( Madrid))
Collantes Rodríguez, Cristina (Hospital Regional Universitario de Málaga)
España, Agustín (Clínica Universidad de Navarra)
Fonseca Capdevila, Eduardo (Complejo Hospitalario Universitario de A Coruña)
Gil Faure, Inmaculada (Hospital Universitari de Sant Joan de Reus (Reus, Catalunya))
Hernández Fernández, Carlos Pelayo (Hospital Universitario de Gran Canaria Dr. Negrín)
Melgosa Ramos, Francisco Javier (Hospital Lluís Alcanyís de Xàtiva)
Spertino, Jorge Luis (Institut de Recerca Sant Pau)
Zaragoza Ninet, Violeta (Hospital General Universitario de Valencia)
Armillas, Lucia (Hospital Comarcal de Inca (Mallorca))
Bielsa, Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Carrera, Cristina (Hospital Clínic i Provincial de Barcelona)
Esquius Rafat, Mireia (Xarxa Assistencial Universitària de Manresa)
Barbarin, Jon Fulgencio (Hospital Universitario 12 de Octubre (Madrid))
Fernandez Vela, Javier (Hospital General de Granollers)
Lova Navarro, Miguel (Hospital Universitario Virgen de la Arrixaca (Múrcia))
Martín Callizo, Clara (Hospital Universitari Joan XXIII de Tarragona)
Martín-Sala, S. (Hospital Dos de Maig (Barcelona, Catalunya))
Ojeda, R. (Parc Sanitari Sant Joan de Déu)
Parera-Amer, María Elisabet (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears))
Sánchez-Puigdollers, A. (Hospital Universitari Sagrat Cor (Barcelona, Catalunya))
Pujol Vallverdú, Ramón M. (Institut Hospital del Mar d'Investigacions Mèdiques)
Podlipnik, Sebastian (Hospital Clínic i Provincial de Barcelona)
Curto-Barredo, L. (Institut Hospital del Mar d'Investigacions Mèdiques)

Data:	2025
Resum:	Background: Bullous pemphigoid (BP) affects elderly individuals with multiple comorbidities, making conventional treatments unsuitable. Objectives: Evaluate the effectiveness and safety of dupilumab in the treatment of BP. Methods: A multicentre ambispective cohort study was conducted across 34 hospitals. Patients with BP treated with dupilumab were included. Most of the patients (97. 1%) received an initial 600-mg dose followed by 300mg every 2 weeks. The primary outcome was the proportion of patients achieving complete remission (CR) within 4 weeks, defined as an Investigator's Global Assessment score of 0 or 1. CR at weeks 16, 24 and 52, adverse events (AEs), reductions in Peak Pruritus Numerical Rating Scale (PP-NRS) and systemic glucocorticoid use were also assessed. Results: The study included 103 patients with a median age of 77. 3years; 58. 3% were male. CR was achieved by 53. 4% within 4 weeks and 95. 7% by week 52. The PP-NRS score reduced by 70. 0% by week 4 and was completely controlled by week 24. Thirteen patients presented with AEs, most of which were mild. Systemic glucocorticoid use reduced by 82. 1% by week 52. Shorter disease duration and exclusive cutaneous involvement predicted better response at 16 weeks. No differences in response rates to dupilumab were observed between drug-associated BP and idiopathic cases. No significant difference in response rates was observed between patients treated with dupilumab in monotherapy and those receiving dupilumab with concomitant treatments. Conclusions: Dupilumab is effective, rapid and safe in managing BP, reducing the need for corticosteroids and other treatments. Early initiation and exclusive skin involvement predict better outcomes.
Drets:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Llengua:	Anglès
Document:	Article ; recerca ; Versió acceptada per publicar
Matèria:	Bullous Pemphigoid ; Treatment ; Dupilumab
Publicat a:	British journal of dermatology, Vol. 192, Num. 3 (February 2025) , p. 501-509, ISSN 1365-2133

DOI: 10.1093/bjd/ljae403

Postprint 26 p, 791.9 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats